SINGAPORE (Dec 18): Catalist-listed iX Biopharma has launched a line of nutraceuticals that could help it turn a profit sooner than it could have done through the development of its pain management, erectile dysfunction and opioid treatment drugs. The products could also improve market sentiment toward its stock price, which hit an all-time low of 18.4 cents two months ago and is more than 50% off its IPO price two years ago.

Have a premium account? Sign in to continue reading.

Unlimited access to all stories from $99.9/year*

The latest reporting and analysis from business and investments to news and views on social issues.


  • Simultaneous logins across all devices
  • Instant access to past digital issues
  • Unlimited access to The Edge Malaysia
  • *For annual subscription plan only. T&Cs apply